Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Therapeutic Margin for Geographic Atrophy

Therapeutic Margin for Geographic Atrophy Therapeutic Margin for Geographic Atrophy Invited Commentary Invited Commentary The Race Between Longevity and Disease Progression SriniVas R. Sadda, MD; David Sarraf, MD Effective treatment for geographic atrophy (GA) associated with In this context, population-based age-related macular de- age-related macular degeneration remains an elusive and generation epidemiology studies such as the Rotterdam Study unmet need in ophthalmology. A number of potential therapeu- and the Blue Mountains Eye Study have proven to be valuable 1,2 tic agents are currently resources to better capture the true burden of disease. The 4 co- under evaluation at various hort studies analyzed (Rotterdam Study I, II, and III and Blue Related article Mountains Eye Study) included more than 18 000 participants stages of investigation includ- ing phase 3 clinical trials. Even older than 45 years from the Netherlands and Australia, who if these agents prove to be effective, it appears that they can at were followed up up to 15 (Australia) or 25 (the Netherlands) best slow but not stop the progression of the disease. However, years. Individuals were evaluated with imaging approximately slowing progression may be a remarkable and meaningful out- every 5 years. The precise imaging protocols and procedures ob- come if http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Therapeutic Margin for Geographic Atrophy

JAMA Ophthalmology , Volume 139 (7) – Jul 20, 2021

Loading next page...
 
/lp/american-medical-association/therapeutic-margin-for-geographic-atrophy-qBX0GW00cw
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2021.1414
Publisher site
See Article on Publisher Site

Abstract

Therapeutic Margin for Geographic Atrophy Invited Commentary Invited Commentary The Race Between Longevity and Disease Progression SriniVas R. Sadda, MD; David Sarraf, MD Effective treatment for geographic atrophy (GA) associated with In this context, population-based age-related macular de- age-related macular degeneration remains an elusive and generation epidemiology studies such as the Rotterdam Study unmet need in ophthalmology. A number of potential therapeu- and the Blue Mountains Eye Study have proven to be valuable 1,2 tic agents are currently resources to better capture the true burden of disease. The 4 co- under evaluation at various hort studies analyzed (Rotterdam Study I, II, and III and Blue Related article Mountains Eye Study) included more than 18 000 participants stages of investigation includ- ing phase 3 clinical trials. Even older than 45 years from the Netherlands and Australia, who if these agents prove to be effective, it appears that they can at were followed up up to 15 (Australia) or 25 (the Netherlands) best slow but not stop the progression of the disease. However, years. Individuals were evaluated with imaging approximately slowing progression may be a remarkable and meaningful out- every 5 years. The precise imaging protocols and procedures ob- come if

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Jul 20, 2021

References